In addition, effective as of October 4, 2021, the Company has appointed Brian Piekos, the
Companys Chief Financial Officer, the additional title of Chief Business Officer, and Mr. Piekos has assumed additional leadership responsibilities for various functions including manufacturing, business development and investor
relations. Mr. Piekos will continue to serve as the principal financial officer and principal accounting officer of the Company.
Finally, Georges
Gemayel, Ph.D., will transition to serve as the Executive Chair of the Companys Board. Dr. Gemayel has served as Chair of the Companys Board since May 2021.
Item 7.01 Regulation FD Disclosure
On
October 5, 2021, the Company issued a press release entitled Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy.
The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as expressly set forth by specific reference in such a filing.
Forward-Looking Statements
Certain statements in this Current Report on Form 8-K may constitute forward-looking statements for
purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management teams expectations, hopes, beliefs, intentions or strategies regarding the future, including
those relating to the timing of and costs associated with our planned restructuring, and the benefits we expect to receive from the restructuring, the success, cost and timing of our product development activities and clinical trials, whether such
data, when final, will be consistent with interim reported data, the timing or ability to commence future clinical trials, the potential attributes and benefits of our product candidates, including GEM103, the reliability of the interim or final
results of studies relating to safety and possible adverse effects resulting from the administration of our product candidates, our ability to obtain and maintain regulatory approval for our product candidates, our projected cash runway and our
ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management teams expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words anticipate, believe, contemplate,
continue, could, estimate, expect, intends, may, might, plan, possible, potential, predict, project,
should, will, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based
on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number
of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, those factors described under the heading Risk Factors in Geminis most recent Annual Report on Form 10-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important factors included in any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual
results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there
may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release by Gemini Therapeutics, Inc., dated October 5, 2021
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|